Successful pregnancy and live birth after intrauterine administration of autologous platelet-rich plasma in a woman with recurrent implantation failure: A case report

Farimani, Marzie; Poorolajal, Jalal; Rabiee, Soghra; Bahmanzadeh, Maryam

doi:10.29252/ijrm.15.12.803

Cited by 36 publications

(34 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2017, Farimani et al 32 described the first‐time use of PRP in a 45‐year‐old woman with a history of two embryo implantation failures who underwent an IVF cycle with donor eggs. Dieamant et al recently proposed a new therapeutic protocol to improve endometrial receptivity in which IU infusion of PRP was associated with the systemic use of G‐CSF.…”

Section: Discussionmentioning

confidence: 99%

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Cavalcante

Sarno

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

Studies have investigated the gestational outcomes of new immunological therapies in the treatment of patients with recurrent implantation failure (RIF) in assisted reproductive technology (ART). The objective of this article is to assess the current state of evidence available in the literature on intrauterine perfusion immunotherapies in women undergoing ART treatments. By considering the guidelines of Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA), the authors performed systematic review by searching the databases of PubMed/MEDLINE and Scopus using the following key words: “recurrent implantation failure,” “intrauterine infusion,” “Platelet‐Rich Plasma (PRP),” “Peripheral Blood Mononuclear Cells (PBMC),” “Granulocyte Colony‐Stimulating Factor (G‐CSF),” and “Human Chorionic Gonadotropin (hCG).” The authors analyzed the indications and the impact of new immunological therapies with intrauterine infusions on the pregnancy outcomes of patients undergoing ART. PRP, PBMC, G‐CSF, and hCG were the four most used immunological therapies with intrauterine infusion. These new therapies appear to improve the results of ART treatments in cases of RIF. However, the small number of studies does not allow definitive conclusions about the effectiveness of these therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Cavalcante

Sarno

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…While there are many studies of PRP, which includes several growth factors, in different disciplines, studies conducted in the field of gynecology and obstetrics are limited in the literature. It has been stated that PRP contributes to the endometrial growth and thickening and may be effective in infertility in patients with a thin and weak endometrium 35–37 . Farimani et al have stated that local PRP administration prior to embryo transfer in recurrent implantation failures may improve the success of implantation 38 .…”

Section: Discussionmentioning

confidence: 99%

The Effects of Leukocyte- and Platelet-Rich Plasma (L-Prp) and Pure Platelet-Rich Plasma (P-Prp) an a Rat Endometriosis Model

Anğın

Gün

Sakin

et al. 2019

Preprint

View full text Add to dashboard Cite

29Our aim was to investigate the effect of platelet-rich plasma (PRP) derivatives, which 30 can be produced from the patient's own blood and have minimal side effects, on 31 endometriosis. To the best of our knowledge, this is the first study in the literature that studies 32 the relationship between PRP and endometriosis. Endometriosis foci were created in the first 33 operation. In the second operation (30 th day) groups were formed. Group 1 (n= 8) was 34 administered saline, group 2 (n= 7) leukocyte-and platelet-rich plasma (L-PRP), and group 3 35 (n= 8) pure platelet-rich plasma (P-PRP). Group 4 (n= 10) was used to obtain PRP. In the last 36 operation (60 th day), the endometriotic foci were measured, and then excised. There was no 37 statistically significant difference between the pre and post volumes of the endometriotic foci, 38 between their volume differences and volume difference rates (p > .05). However, it was 39 observed that existing implant volumes in all groups decreased statistically significantly 40 within their own groups by the end of the experiment compared to the previous volumes (p < 41 .05). When the implants were assessed through histopathological scoring in terms of edema, 42 vascular congestion, inflammatory cell infiltration, hemorrhage, epithelial line, and 43 hemosiderin accumulation and immunohistochemical staining in terms of VEGF, there was 44 no significant difference in the comparison between the groups. Although L-PRP and P-PRP 45 generated more reduction in the endometriosis foci, they did not create any statistical 46 differences. 48Endometriosis, which is described as the presence of endometrial gland and stroma 49 outside the uterine cavity, is an important women's health problem seen in 6-10% of women 50 that causes degradation in the quality of life with clinical effects, such as infertility, 3 51 dysmenorrhea, dyspareunia and chronic pelvic pain 1-4 . Its pathophysiology has not yet been 52 fully resolved, and an effective treatment for it has not yet been found 5,6 . 53

show abstract

“…This first report was followed by others [72][73][74] showing an improvement on endometrial growth and fertility treatment outcome in patients with thin endometrium. Last, a case report described the successful pregnancy outcome of a patient diagnosed with recurrent implantation failure treated with autologous PRP intrauterine administration prior to embryo transfer [75]. Data presented on a recent report [72] suggests that PRP intrauterine infusion promotes neo-angiogenesis.…”

Section: Platelet-rich Plasma and Endometrial Receptivitymentioning

confidence: 99%

Platelet-rich plasma or blood-derived products to improve endometrial receptivity?

Bös-Mikich

Ferreira

Oliveira³

et al. 2019

J Assist Reprod Genet

View full text Add to dashboard Cite

The use of platelet-rich plasma (PRP) to improve endometrial receptivity is gaining increasing attention in assisted reproduction technologies. The authors report that autologous PRP intrauterine administration improves pregnancy and birth rates, particularly in cases of patients presenting poor endometrial growth. Different groups of scientists proposed a similar approach years ago using whole blood-derived products also to improve endometrial receptivity. The important role played by cytokines and growth factors during embryo implantation has been well-known for a long time. These signaling molecules are present and released by blood cells during physiological, normal endometrial growth and implantation. Similar blood mediators are released from platelet granules upon a blood vessel injury. Methods described for PRP preparation for intrauterine administration are not precise, and they seem to be similar to those used to prepare peripheral blood-derived products. Thus, it is possible that when preparing PRP from whole blood, the final plasma product used as BPRP^contains platelets in addition to the important cytokines and growth factors released by the peripheral blood mononuclear cells present in the whole blood. Precise knowledge of the identity, concentration, and effects of the individual blood factors, their origin, whether platelets or blood mononuclear cells, will greatly contribute to improve and to make results obtained in fertility treatments more repeatable.

show abstract

Successful pregnancy and live birth after intrauterine administration of autologous platelet-rich plasma in a woman with recurrent implantation failure: A case report

Cited by 36 publications

References 12 publications

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

Intrauterine perfusion immunotherapies in recurrent implantation failures: Systematic review

The Effects of Leukocyte- and Platelet-Rich Plasma (L-Prp) and Pure Platelet-Rich Plasma (P-Prp) an a Rat Endometriosis Model

Platelet-rich plasma or blood-derived products to improve endometrial receptivity?

Contact Info

Product

Resources

About